TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers report that lower levels of the protective protein NRF2 in oligodendrocytes are associated with faster cognitive decline and abnormal myelin in older adults. In mice, reducing NRF2 in these cells produced similar brain changes, but the findings do not show that an existing drug can prevent cognitive decline in people.
Researchers from the University of Edinburgh and the UK Dementia Research Institute report that oligodendrocytes—brain cells that maintain the insulating myelin around nerve fibers—may contribute to age-related cognitive decline when they become dysfunctional. Their study, published in Nature Medicine, found that lower levels of the protective protein NRF2 in these cells were associated with faster decline in people, while experiments in mice linked reduced NRF2 to abnormal myelin and loss of large nerve fibers.
The human findings draw on the Lothian Birth Cohort 1936, whose members have had their cognitive abilities tracked from childhood into later life. Of 1,091 people enrolled, 866 completed additional testing after age 70. Researchers assessed memory, processing speed and spatial reasoning between ages 70 and 82. Nearly all participants experienced some decline, but its pace varied.
After some participants died, researchers examined their brain tissue. People whose cognitive abilities had declined more quickly tended to have fewer large nerve fibers and an abnormal buildup of myelin, the coating that helps nerve signals travel efficiently. These tissue findings were associated with the rate of decline over time, rather than a person’s cognitive test performance at a single age.
The team also found that participants with greater decline had lower NRF2 levels in oligodendrocytes. NRF2 regulates genes involved in cellular defenses and normal function. In mice, selectively reducing NRF2 in oligodendrocytes led to excessive myelin, loss of large nerve fibers and weaker improvement in cognitive performance as the animals aged. The researchers say the animal experiments support a possible causal role for the pathway, but do not establish that it causes human cognitive decline.
A New Target in Aging Brain Cells
The findings challenge the assumption that myelin-producing cells are always protective. Oligodendrocytes are needed to maintain nerve fibers, but the study suggests that age-related changes in their function may disrupt myelin and damage the fibers they support. That could offer researchers another way to investigate why some older adults experience faster declines in memory and thinking than others.
The work also identifies NRF2 as a possible research target. The pathway is acted on by drugs used for other neurological conditions, including multiple sclerosis. However, the study does not test those drugs as a treatment for age-related decline, and it provides no evidence that older adults should use them for that purpose. Any future application would require research on safety and effectiveness in the relevant population.
NRF2 supplement for cognitive health
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From Cohort Records to Mouse Tests
The cohort’s long-running cognitive records let researchers compare changes across adulthood with brain tissue collected after death. That combination gave the team a way to look for biological features linked to the pace of decline, rather than relying only on a test taken late in life. The tissue analysis found associations; by itself, it cannot establish whether the myelin abnormalities preceded or followed cognitive changes.
The researchers then used mice to test whether reducing NRF2 specifically in oligodendrocytes could produce related changes. The resulting nerve-fiber and myelin abnormalities resembled those observed in human tissue. These experiments add evidence that the cell pathway can affect brain structure and cognitive performance in animals, while leaving open how closely the process maps onto aging in people.
““As the prevalence of cognitive decline is rising with an aging population and no current treatments exist, we are excited about this work as it points to a potential strategy for new therapeutic strategies to preserve cognitive ability in aging.””
— Veronique Miron, MRC Senior Non-Clinical Fellow and UK Dementia Research Institute group leader at the University of Edinburgh and St. Michael’s Hospital
oligodendrocyte support supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Human Treatment Evidence Is Missing
The human results show associations between faster cognitive decline, lower NRF2 levels in oligodendrocytes and myelin abnormalities. They do not prove that reduced NRF2 is the cause of decline in people, or that changing the pathway would prevent it. The mouse experiments strengthen the case for a biological connection but cannot answer whether a drug would be safe or effective for older adults.
The source report does not specify whether the researchers tested an NRF2-targeting medication in the cohort or in the reported mouse experiments. It also does not establish which patients might benefit, when treatment would need to begin, or whether the abnormal myelin changes can be reversed. These questions require further study.
As an affiliate, we earn on qualifying purchases.
Testing the Pathway in People
The next step is to determine whether altering NRF2 activity can protect myelin and nerve fibers in relevant preclinical models, and whether those effects translate to human cognitive outcomes. Researchers would also need to establish appropriate doses, potential risks and which groups could be suitable for trials before an existing drug could be considered for this use.
For now, the study offers a possible direction for research rather than a treatment recommendation. Its central finding is that supportive brain cells may become part of the problem as the brain ages; whether targeting that change can preserve cognition in people remains to be shown.
brain health supplements for aging
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are oligodendrocytes?
Oligodendrocytes are brain cells that produce and maintain myelin, the insulating coating around nerve fibers. Myelin helps electrical signals travel through the brain.
What did the researchers find in people?
In brain tissue from members of a long-running cohort, faster cognitive decline was associated with fewer large nerve fibers, abnormal myelin buildup and lower NRF2 levels in oligodendrocytes. These findings are associations, not proof of cause.
Did the study show that an existing drug prevents cognitive decline?
No. The report notes that drugs targeting the NRF2 pathway are used for other conditions, but this study does not show that those medicines prevent or treat age-related cognitive decline.
Why were mice included in the research?
Researchers reduced NRF2 in oligodendrocytes in mice to test the pathway’s effects. The animals developed myelin and nerve-fiber changes resembling those found in human tissue and showed weaker improvement in cognitive performance with age. Animal results do not establish a treatment effect in people.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
